Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022, 11, 2367
1. Error in Table
2. Text Correction
- Section 3, Section 3.1, Paragraph 1, from fifth to seventh sentences should be: “There were 22 female (55%) and 18 male (45%) patients negative for perineural invasion (Pn0 group) with a median age of 64.7 years (range 35–84). The group of patients positive for perineural invasion (Pn1 group) consisted of 242 female (45.6%) and 289 male (54.4%) individuals with a median age of 65.6 years (range 37–83). Tumor location in over 70% of both groups was the head of the pancreas (Pn0 group: 70 %, Pn1 group: 75.1%), followed by the pancreatic tail (Pn0 group: 17.5%, Pn1 group: 11.9%) and pancreatic body (Pn0 group: 7.5%, Pn1 group: 8.1%).”
- Section 3, Section 3.2, Paragraph 2, the last two sentence should be: “There was a significant difference between the BMI of the Pn0 and Pn1 group (p = 0.05). Pre-operative tumor markers (CA19-9, CEA) that well reflect the overall tumor burden, including micro-metastases, did not reveal strong correlations.”
- Section 3, Section 3.3, the first sentence should be: “Studying long-term survivors (LTS with survival >5 years) in our study cohorts, we discriminated a significantly increased number of LTS in the Pn0 group compared to Pn1 patients (p = 0.04).”
- Section 3, Section 3.2, Paragraph 1, from third to fifth sentences should be: “In our cohort, 30% of Pn0 patients presented with early stage pT1 tumors (Pn0, pT1: 30%; Pn0, pT2: 50%; Pn0, pT3: 20%; Pn0, pT4: 0%), while only 10.5% of Pn1 patients presented with pT1 tumors (Pn1, pT1: 10.5%; Pn1, pT2: 57.1%; Pn1, pT3: 27.9%; Pn1, pT4: 4.5%; p = 0.007). The majority of Pn1 tumors showed lymph node metastasis (Pn1, pN+: 75.5% versus Pn1, pN0: 24.5%), while lymph node infiltration occurred only in 40% of Pn0 tumors (Pn0, pN+: 40% versus Pn0, pN0: 60%; p < 0.001). This also significantly correlated with lymphatic invasion; 44.1% of the Pn1 tumors were positive for lymphatic invasion (Pn1 L1: 44.1%; Pn1 L0: 55.9%).”
- Section 3, Section 3.2, Paragraph 1, the last two sentence should be: ”There also appeared to be a detectable difference in the grading of Pn1 tumors compared to Pn0 tumors with a shift toward less-differentiated tumors in the Pn1 group (Pn1 G1: 3%; Pn1 G2: 60.5%; Pn1 G3: 36.5%—Pn0 G1: 10%; Pn0 G2: 67.5%; Pn0 G3: 22.5%; p = 0.03). However, vascular invasion and resection margin did not significantly correlate with either Pn0 or Pn1 tumors.”
Reference
- Felsenstein, M.; Lindhammer, F.; Feist, M.; Hillebrandt, K.H.; Timmermann, L.; Benzing, C.; Globke, B.; Zocholl, D.; Hu, M.; Fehrenbach, U.; et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022, 11, 2367. [Google Scholar] [CrossRef] [PubMed]
Total | % | Pn0 | % | Pn1 | % | Statistics * | |
---|---|---|---|---|---|---|---|
Cases | 571 | 40 | 531 | ||||
Age (years) | 65.6 (+/−11.1) | 64.7 (+/−10.5) | 65.6 (+/−10.8) | p = 0.58 | |||
Sex | female 264 | 46.2 | female 22 | 55 | female 242 | 45.6 | p = 0.26 |
male 307 | 53.8 | male 18 | 45 | male 289 | 54.4 | ||
Body mass index (BMI) (in kg/m2) | 25.1 (+/−4.3) | 23.6 (+/−4.0) | 25.2 (+/−4.3) | p = 0.05 | |||
Diabetes mellitus (DM) | |||||||
DM I | 19 | 3.3 | 0 | 0 | 19 | 3.6 | p = 0.39 |
DM II | 116 | 20.3 | 7 | 17.5 | 109 | 20.5 | p = 0.84 |
Beta blocker | p = 0.22 | ||||||
ß1 selective | 168 | 29.4 | 9 | 22.5 | 159 | 29.9 | |
Non-selective | 12 | 2.1 | 0 | 0 | 12 | 2.3 | |
Carbohydrate-antigen 19-9 (in U/mL) | 846.3 (+/−3014) | 453.6 (+/−1303) | 888.5 (+/−3142) | p = 0.49 | |||
Carcinoembryonic antigen (in µg/L) | 18.8 (+/−67.9) | 4.5 (+/−3.2) | 20.0 (+/−72.9) | p = 0.28 | |||
Tumor entity | p = 0.77 | ||||||
Head | 427 | 74.8 | 28 | 70 | 399 | 75.1 | |
Tail | 70 | 12.3 | 7 | 17.5 | 63 | 11.9 | |
Body | 46 | 8.1 | 3 | 7.5 | 43 | 8.1 | |
Uncinate | 28 | 4.9 | 2 | 5 | 26 | 4.9 | |
Surgical procedure | p = 0.05 | ||||||
PPPD ** | 363 | 63.6 | 20 | 50 | 343 | 64.6 | |
Whipple | 29 | 5.1 | 5 | 12.5 | 24 | 4.5 | |
Total | 94 | 16.5 | 6 | 15 | 88 | 16.5 | |
Distal | 85 | 14.9 | 9 | 22.5 | 76 | 14.3 | |
Chemotherapy | |||||||
Pre-operative | 64 | 11.2 | 8 | 20 | 56 | 10.5 | p = 0.11 |
Post-operative | 353 | 61.8 | 28 | 70 | 325 | 61.2 | p = 0.31 |
Clinical Outcome | |||||||
Follow-up (months) | 17.2 | 24.2 | 16.6 | p = 0.04 | |||
30-day mortality | 28 | 5.2 | 0 | 0 | 28 | 5.6 | p = 0.25 |
Death | 383 | 78.8 | 15 | 41.7 | 368 | 81.8 | p < 0.001 |
Alive | 103 | 18.0 | 21 | 52.5 | 82 | 15.4 | p < 0.001 |
Lost to follow-up | 85 | 14.9 | 4 | 10 | 81 | 15.3 | p = 0.49 |
LTS *** (>5 years) | 19 | 3.3 | 4 | 10 | 15 | 2.8 | p = 0.04 |
Recurrence | |||||||
Yes | 167 | 29.2 | 11 | 27.5 | 156 | 29.4 | p = 0.86 |
No | 404 | 70.8 | 29 | 72.5 | 375 | 70.6 |
Total | % | Pn0 | % | Pn1 | % | Statistics * | |
---|---|---|---|---|---|---|---|
Cases | 571 | 40 | 531 | ||||
Tumor stage | p = 0.007 | ||||||
pT1 (<2 cm) | 68 | 11.9 | 12 | 30 | 56 | 10.5 | |
pT2 (2–4 cm) | 323 | 56.6 | 20 | 50 | 299 | 57.1 | |
pT3 (>4 cm) | 176 | 27.3 | 8 | 20 | 148 | 27.9 | |
pT4 (vessel infiltration) | 24 | 4.2 | 0 | 0 | 24 | 4.5 | |
Lymph node metastasis | p < 0.001 | ||||||
N− | 154 | 27 | 24 | 60 | 130 | 24.5 | |
N+ | 417 | 73 | 16 | 40 | 401 | 75.5 | |
Distant metastasis | p = 0.3 | ||||||
M0 | 510 | 89.3 | 38 | 95 | 472 | 88.9 | |
M1 | 61 | 10.7 | 2 | 5 | 59 | 11.1 | |
Histologic grade | p = 0.03 | ||||||
G1 | 20 | 3.5 | 4 | 10 | 16 | 3 | |
G2 | 348 | 60.9 | 27 | 67.5 | 321 | 60.5 | |
G3 | 203 | 35.6 | 9 | 22.5 | 194 | 36.5 | |
Resection margin | p = 0.06 | ||||||
R0 | 359 | 62.9 | 31 | 77.5 | 328 | 61.8 | |
R1 | 212 | 37.1 | 9 | 22.5 | 203 | 38.2 | |
Vascular invasion | p = 0.09 | ||||||
V0 | 467 | 81.8 | 37 | 92.5 | 430 | 81 | |
V1 | 104 | 18.2 | 3 | 7.5 | 101 | 19 | |
Lymphatic invasion | p < 0.001 | ||||||
L0 | 330 | 57.8 | 33 | 82.5 | 297 | 55.9 | |
L1 | 241 | 42.2 | 7 | 17.5 | 234 | 44.1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Felsenstein, M.; Lindhammer, F.; Feist, M.; Hillebrandt, K.H.; Timmermann, L.; Benzing, C.; Globke, B.; Zocholl, D.; Hu, M.; Fehrenbach, U.; et al. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022, 11, 2367. J. Clin. Med. 2023, 12, 6947. https://doi.org/10.3390/jcm12216947
Felsenstein M, Lindhammer F, Feist M, Hillebrandt KH, Timmermann L, Benzing C, Globke B, Zocholl D, Hu M, Fehrenbach U, et al. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022, 11, 2367. Journal of Clinical Medicine. 2023; 12(21):6947. https://doi.org/10.3390/jcm12216947
Chicago/Turabian StyleFelsenstein, Matthäus, Flora Lindhammer, Mathilde Feist, Karl Herbert Hillebrandt, Lea Timmermann, Christian Benzing, Brigitta Globke, Dario Zocholl, Mengwen Hu, Uli Fehrenbach, and et al. 2023. "Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022, 11, 2367" Journal of Clinical Medicine 12, no. 21: 6947. https://doi.org/10.3390/jcm12216947